Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers

NCT ID: NCT01064050

Last Updated: 2015-07-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE4

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-11-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A tumoral obstruction of the main stem bronchus is frequently observed in the follow-up of lung cancers with a high impact on survival and quality of life of these patients. The endoluminal resection of these tumors through interventional bronchoscopy can remove the tumor but fails to prevent the recurrence. A stent insertion could achieve this goal but this option was never proved in a prospective protocol.

The aim of this study is to analyze the impact of stent insertion on the survival without symptoms of bronchial obstruction in patients treated for their cancer with and without a first line treatment (chemo-radiotherapy or chemotherapy). The patients will be included after resection of the endoluminal symptomatic tumoral obstruction. We will test the effect of the silicone stent insertion ( from NovatechR ) by comparing a stent arm (170 patients with stent insertion) with a control arm (170 patients without stent). The inclusion period will last 3 years with one year of follow-up for each patient. The one-year survival without symptomatic recurrence (proved on bronchoscopy with more than 50% of obstruction in the treated zone) will be the main endpoint. All patients without symptomatic recurrence at one year will be controlled endoscopically. Survival and stent tolerance will be studied as secondary endpoints. All endoscopic events will be depicted on photographs or videos. Each endoscopical situation (before and after resection, recurrence or side effects of stents) will be analyzed and registered by an independent committee of 3 international experts.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Neoplasm Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

trachea-bronchial stent (Novatech)

Group Type EXPERIMENTAL

silicone trachea-bronchial stent Dumon (Novatech)

Intervention Type DEVICE

Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area

control

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

silicone trachea-bronchial stent Dumon (Novatech)

Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \> 18 years
* non-small cell lung cancer,
* inoperable and location : tracheal, carinal, main bronchus right or left, or intermediate trunk.
* TNM stage known and oncological treatment later determined
* central initial intrinsic bronchial obstruction \> 50%.
* resection of tumor with endoscopy, to obtain after therapeutic bronchoscopy a diameter \> 50% normal diameter of bronchial segment achieved.
* Tumoral segment fully recoverable by a stent
* Written consent, free and informed
* Patient affiliated or who is entitled to to a social security scheme.

Exclusion Criteria

* against-indication for general anesthesia.
* Patient with one lung not working beyond the stenosis
* Patient under guardianship
* Pregnancy
* 12 months follow-up impossible
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ministry of Health, France

OTHER_GOV

Sponsor Role collaborator

Ligue contre le cancer, France

OTHER

Sponsor Role collaborator

Centre Hospitalier Universitaire de Saint Etienne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jean-Michel Vergnon, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CHU SAINT-ETIENNE

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of pneumology, CHU Amiens

Amiens, , France

Site Status

Departement of pneumology, CHU Brest

Brest, , France

Site Status

Pneumology departement, Hôpital Percy

Clamart, , France

Site Status

Pneumology departement, CHRU Lille

Lille, , France

Site Status

Pneumology departement, CHU Limoges

Limoges, , France

Site Status

Pneumology departement, Sainte Marguerite hospital

Marseille, , France

Site Status

Pneumology departement, CHU Nantes

Nantes, , France

Site Status

Pneumology departement, Saint-Antoine hospital

Paris, , France

Site Status

Department of respiratory diseases and allergic, Thoracic Oncology, CHU Reims

Reims, , France

Site Status

Pneumology Clinic - Albert Calmette hospital- CHU Rouen

Rouen, , France

Site Status

Pneumology departement CHU Saint-Etienne

Saint-Etienne, , France

Site Status

Endoscopy unit, Thoracic surgery department, Foch Hospital

Suresnes, , France

Site Status

Departement of pneumology, CHU TOULOUSE

Toulouse, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2007-A01190-53

Identifier Type: OTHER

Identifier Source: secondary_id

0708042

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.